| Management target | Revenue 110.0% FY27 |
|---|
| Revenue growth | 33.8% YoY (Consolidated) |
|---|---|
| Margins | EBITDA margin expanded to 18.01% in Q1 FY27 vs 14.97% YoY. |
| Demand visibility | Strong underlying demand despite logistics freeze. |
| Management confidence | High; expecting fair recovery from shipping disruptions in Q1. |
Growth
Q1 FY27 Revenue rose 33.8%, EBITDA up 61%, and PAT grew 43.9% YoY on a consolidated basis.
Outlook
FY27 revenue guidance: ₹800-850 Mn (base) + ₹600-650 Mn (IV-fluid). Target EBITDA margins of 16-17%.
Risks
US-Iran conflict disrupted Middle East shipping routes; higher raw material/packing costs in March 2026 compressed gross margins.
Last quarter's promises, checked
Delivered
- Guided Q1 FY27 recovery from March disruptions → Delivered 33.8% YoY growth (= BEAT)
- Guided 17-18% EBITDA margin for IV plant → Delivered 18.01% consolidated (= BEAT)
- Guided Pune IV plant revenue ramp-up from Q3/Q4 FY26 base → Delivered ₹2.7 Cr in Q4 vs ₹1.2 Cr in Q3 (= BEAT)
Partly delivered
- Guided ₹60 Cr annual IV plant revenue → Current Q1 run-rate suggests potential shortfall unless ramp accelerates (= PARTIAL)
Investor Presentation filed with BSE, NSE: SANJIVIN. Summary written with AI assistance from the document.
Sanjivani Paranteral Ltd: key numbers
- Share price
- ₹169.05
- Market cap
- ₹207.7 Cr
- Revenue (annual)
- ₹68.67 Cr
- Net profit (annual)
- ₹6.79 Cr
- P/E (TTM)
- 19.7×Sector 50.4×
- Promoter holding
- 31.56%+0.30% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sanjivani Paranteral Ltd
All →Sanjivani Paranteral Fund Raise
Sanjivani Paranteral clarified the objects of its proposed 5 lakh convertible warrant issue to BSE. Proceeds of ~₹5.80 Cr will fund capex and subsidiary working capital for expansion.
Sanjivani Paranteral Annual General Meeting
Sanjivani Paranteral Limited held its 32nd Annual General Meeting on September 16, 2026. The meeting concluded with resolutions on financial statements and director re-appointment.
Sanjivani Paranteral Q1 FY27 Results: Net Profit ₹2.5 Cr, Up 47.1% YoY
Sanjivani Paranteral Ltd reported revenue from operations of ₹23.8 Cr (+33.0% YoY) and net profit of ₹2.5 Cr (+47.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹2.5 Cr · +47.1% YoY
Sanjivani Paranteral Earnings Call: Key Takeaways
Sanjivani Paranteral Q4 FY26 earnings transcript. Management transitions to a multi-vertical platform with base formulation business and new IVF and nutraceutical ventures.
Sanjivani Paranteral Earnings Call: Key Takeaways
Sanjivani Paranteral's Q4 & FY26 presentation shows significant decline in standalone financials. Focus remains on injectables (53.5% FY26 revenue) and export markets (78.5% FY26 revenue).
Sanjivani Paranteral Q4 FY26 Results: Net Profit ₹0.5 Cr, Down 77.3% YoY
Sanjivani Paranteral Ltd reported revenue from operations of ₹13.2 Cr (-27.5% YoY) and net profit of ₹0.5 Cr (-77.3% YoY) for Q4 FY26.
- Key figure
- Net profit ₹0.5 Cr · -77.3% YoY